Clinical use of dendritic cells for cancer therapy

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages

  Anguille, Sébastien ^a,b   Smits, Evelien L ^a,c   Lion, Eva ^b   Van Tendeloo, Viggo F ^b   Berneman, Zwi N ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD40 LIGAND; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; SUNITINIB; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT RESPONSE; TREND STUDY; TUMOR VOLUME;

DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR BURDEN; VACCINATION;

EID: 84901405092     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70585-0     Document Type: Review

References (120)

1. Steinman RM, Cohn ZA Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973, 137:1142-1162.
2. Palucka K, Banchereau J Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
3. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S Immunotherapy of cancer in 2012. CA Cancer J Clin 2012, 62:309-335.
4. Tacken PJ, de Vries IJ, Torensma R, Figdor CG Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
5. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006, 17:563-570. the DC study group of the DeCOG.
6. Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011, 6:e18801.
7. Amos SM, Duong CP, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011, 118:499-509.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
9. Leonhartsberger N, Ramoner R, Falkensammer C, et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol Immunother 2012, 61:1407-1413.
10. Widén K, Mozaffari F, Choudhury A, Mellstedt H Overcoming immunosuppressive mechanisms. Ann Oncol 2008, 19(suppl 7):vii. 241-47.
11. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF NK cells: key to success of DC-based cancer vaccines?. Oncologist 2012, 17:1256-1270.
12. Boudreau JE, Bridle BW, Stephenson KB, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009, 17:1465-1472.
13. Rosenberg SA, Yang JC, Restifo NP Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
14. Huber ML, Haynes L, Parker C, Iversen P Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012, 104:273-279.
15. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
16. Weber J Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008, 13(suppl 4):16-25.
17. Tay M-H, Nakabayashi M, Oh WK Management of hormone refractory prostate cancer. Comprehensive textbook of genitourinary oncology 2006, 341-354. Lippincott Williams & Wilkins, Philadelphia, PA. 3 edn. N.J. Vogelzang, P.T. Scardino, W.U. Shipley, F.M.J. Debruyne, W.M. Linehan (Eds.).
18. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, 1. CD001425.
19. Madan RA, Gulley JL, Fojo T, Dahut WL Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010, 15:969-975.
20. Saad ED, Buyse M Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?. J Clin Oncol 2012, 30:1750-1754.
21. Thurner B, Haendle I, Röder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999, 190:1669-1678.
22. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003, 21:4016-4026.
23. Dillman R, Selvan S, Schiltz P, et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm 2004, 19:658-665.
24. Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm 2009, 24:311-319.
25. Dillman RO, Cornforth AN, Depriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012, 35:641-649.
26. Trefzer U, Herberth G, Wohlan K, et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 2004, 110:730-740.
27. Vilella R, Benítez D, Milà J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 2004, 53:651-658.
28. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006, 13:905-918.
29. Nakai N, Asai J, Ueda E, Takenaka H, Katoh N, Kishimoto S Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol 2006, 33:462-472.
30. Nakai N, Katoh N, Kitagawa T, Ueda E, Takenaka H, Kishimoto S Evaluation of survival in Japanese stage IV melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cells. J Dermatol 2008, 35:801-803.
31. Hersey P, Halliday GM, Farrelly ML, DeSilva C, Lett M, Menzies SW Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother 2008, 57:1039-1051.
32. Ellebaek E, Engell-Noerregaard L, Iversen TZ, et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 2012, 61:1791-1804.
33. Oshita C, Takikawa M, Kume A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012, 28:1131-1138.
34. Aarntzen EH, De Vries IJ, Lesterhuis WJ, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013, 73:19-29.
35. Tel J, Aarntzen EH, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013, 73:1063-1075.
36. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996, 29:371-380.
37. Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997, 32:272-278.
38. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998, 36:39-44.
39. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
40. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
41. Hildenbrand B, Sauer B, Kalis O, et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate 2007, 67:500-508.
42. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. the IMPACT Study Investigators.
43. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004, 64:4973-4979.
44. Niu H, Dong Z, Dong F, Zhang T, Lei T, Xue D Experimental and clinical research of dendritic cell and syngeneic immunotherapy of brain glioma. Chinese-German J Clin Oncol 2004, 3:147-150.
45. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005, 11:5515-5525.
46. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005, 11:4160-4167.
47. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008, 14:3098-3104.
48. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009, 8:2773-2779.
49. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 2010, 99:261-272.
50. Chang CN, Huang YC, Yang DM, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 2011, 18:1048-1054.
51. Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011, 34:382-389.
52. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011, 17:1603-1615.
53. Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012, 61:2033-2044.
54. Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2012, 77:736-744.
55. Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys 2012, 62:91-99.
56. Valle RD, de Cerio AL, Inoges S, et al. Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol 2012, 3:142-149.
57. Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013, 62:1499-1509.
58. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003, 63:2127-2133.
59. Kim JH, Lee Y, Bae Y-S, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007, 125:257-267.
60. Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008, 31:771-780.
61. Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-alpha2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009, 15:4986-4992.
62. Amin A, Dudek A, Logan T, et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). Proc Am Soc Clin Oncol 2013, 31(suppl 6). abstr 357.
63. Defining clinically meaningful outcomes: ASCO recommendations to raise the bar for clinical trials. 2013 American Society of Clinical Oncology, (accessed May 8, 2014). http://www.asco.org/sites/www.asco.org/files/asco_meaningful_outcomes_draft_for_website_-_05_13_13_0.pdf.
64. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013, 62:137-147.
65. Johnson JR, Williams G, Pazdur R End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003, 21:1404-1411.
66. Sharma P, Wagner K, Wolchok JD, Allison JP Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805-812.
67. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. the TARGET Study Group.
68. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
69. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
70. Hoos A Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012, 23(suppl 8):viii. 47-52.
71. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011, 17:4558-4567.
72. Di Lorenzo G, Buonerba C, Kantoff PW Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011, 8:551-561.
73. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011, 17:907-917.
74. de Vries IJM, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003, 9:5091-5100.
75. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29:330-336.
76. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013, 123:3383-3394.
77. Ueno H, Schmitt N, Klechevsky E, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010, 234:199-212.
78. Romano E, Rossi M, Ratzinger G, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 2011, 17:1984-1997.
79. Anguille S, Lion E, Van Den Bergh J, et al. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother 2013, 9:1956-1961.
80. Boullart AC, Aarntzen EH, Verdijk P, et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 2008, 57:1589-1597.
81. Fujita M, Zhu X, Ueda R, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 2009, 69:1587-1595.
82. Pierret L, Wilgenhof S, Corthals J, Roelandt T, Thielemans K, Neyns B Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated with ipilimumab. Proc Am Soc Clin Oncol 2009, 27(suppl). abstr e20006.
83. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009, 15:6267-6276.
84. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
85. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
86. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008, 13:859-875.
87. Whiteside TL Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010, 10:1019-1035.
88. Shimizu K, Fields RC, Giedlin M, Mulé JJ Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999, 96:2268-2273.
89. Escobar A, López M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005, 142:555-568.
90. Redman BG, Chang AE, Whitfield J, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008, 31:591-598.
91. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006, 66:9299-9307.
92. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G The anticancer immune response: indispensable for therapeutic success?. J Clin Invest 2008, 118:1991-2001.
93. Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med 2013, 11:135.
94. Chen G, Emens LA Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 2013, 62:203-216.
95. Wang LX, Li R, Yang G, et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005, 65:10569-10577.
96. Kandalaft LE, Powell DJ, Chiang CL, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology 2013, 2:e22664.
97. Schlom J Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104:599-613.
98. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol 2012, 13:e32-e42.
99. Jacobs JF, Punt CJ, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010, 16:5067-5078.
100. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633.
101. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112:610-618.
102. Baur AS, Lutz MB, Schierer S, et al. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Blood 2013, 122:2185-2194.
103. Yamada Y, Aoyama A, Tocco G, et al. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates. J Immunol 2012, 188:6063-6070.
104. Radojcic V, Bezak KB, Skarica M, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 2010, 59:137-148.
105. Heine A, Held SA, Bringmann A, Holderried TA, Brossart P Immunomodulatory effects of anti-angiogenic drugs. Leukemia 2011, 25:899-905.
106. Sakamaki I, Kwak LW, Cha SC, et al. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 2014, 28:329-337.
107. Najjar YG, Finke JH Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013, 3:49.
108. Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012, 61:827-838.
109. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011, 71:2664-2674.
110. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013, 133:1653-1663.
111. Knight DA, Ngiow SF, Li M, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013, 123:1371-1381.
112. Ott PA, Henry T, Baranda SJ, et al. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 2013, 62:811-822.
113. Gulley JL, Madan RA, Schlom J Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011, 18:e150-e157.
114. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010, 107:13824-13829.
115. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012, 14:647-656.
116. Gabrilovich DI Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007, 8:2-3.
117. Wheeler CJ, Das A, Liu G, Yu JS, Black KL Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004, 10:5316-5326.
118. Bracci L, Schiavoni G, Sistigu A, Belardelli F Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014, 21:15-25.
119. Aragon-Ching JB, Williams KM, Gulley JL Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007, 12:4957-4971.
120. Kalbasi A, June CH, Haas N, Vapiwala N Radiation and immunotherapy: a synergistic combination. J Clin Invest 2013, 123:2756-2763.